Metformin improves cardiac function in rats via activation of AMP-activated protein kinase

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 2, 2011, Pages 94-101

  Wang, Xiao Fang ^a   Zhang, Jin Ying ^a   Li, Ling ^a   Zhao, Xiao Yan ^a   Tao, Hai Long ^a   Zhang, Li ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

AMP activated protein kinase; Chronic heart failure; Endothelial nitric oxide synthase; Metformin; Transforming growth factor 1

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; BASIC FIBROBLAST GROWTH FACTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INSULIN; METFORMIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY OCCLUSION; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME PHOSPHORYLATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE SIZE; LEFT CORONARY ARTERY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; HEART FAILURE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NITRIC OXIDE SYNTHASE TYPE III; RANDOM ALLOCATION; RATS; RATS, WISTAR; RIBONUCLEOTIDES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 79251477152     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05470.x     Document Type: Article

References (44)

1. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006; 55: 496-505.
2. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000; 3: 607-14.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patient with Type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
4. Solskov L, Lofgren B, Kristiansen SB et al. Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24hours after administration. Basic Clin. Pharmacol. Toxicol. 2008; 103: 82-7.
5. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am. J. Cardiol. 1974; 34: 29-34.
6. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in Type 2 diabetes: An update. Diabetes Care 2004; 27: 1879-84.
7. Eurich DT, McAlister FA, Blackburn DF et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review. BMJ 2007; 335: 497-507.
8. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001; 108: 1167-74.
9. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J. Biol. Chem. 1995; 270: 17513-20.
10. Russell RR III, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Physiol. 1999; 277: H643-9.
11. Marsin AS, Bertrand L, Rider MH et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr. Biol. 2000; 10: 1247-55.
12. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: Possible roles in Type 2 diabetes. Am. J. Physiol. 1999; 277: E1-10.
13. Kimura N, Tokunaga C, Dalal S et al. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 2003; 8: 65-79.
14. Bhalla RC, Toth KF, Tan E, Bhatty RA, Mathias E, Sharma RV. Vascular effects of metformin: Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am. J. Hypertens. 1996; 9: 570-6.
15. Marfella R, Acampora R, Verrazzo G et al. Metformin improves hemodynamic and rheological responses to l-arginine in NIDDM patients. Diabetes Care 1996; 19: 934-9.
16. Katakam PV, Ujhelyi MR, Hoenig M, Miller AW. Metformin improves vascular function in insulin-resistant rats. Hypertension 2000; 35: 108-12.
17. Nagaya N, Fujiii T, Iwase T et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am. J. Physiol. Heart Circ. Physiol. 2004; 287: H2670-6.
18. Ryoke T, Gu Y, Mao L et al. Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition. Circulation 1999; 100: 1734-43.
19. Iwanaga Y, Hoshijima M, Gu Y et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J. Clin. Invest. 2004; 113: 727-36.
20. Sheehan FH, Bolson EL, Dodge HT, Mathey DG, Schofer J, Woo HW. Advantages and applications of the centerline method for characterizing regional ventricular function. Circulation 1986; 74: 293-305.
21. Schiller NB, Shah PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J. Am. Soc. Echocardiogr. 1989; 2: 358-67.
22. Thrinder P. Determination of glucose in blood using glucose oxidase with alternate oxygen acceptor. Ann. Clin. Biochem. 1969; 6: 24-5.
23. -ΔΔCt method. Methods 2001; 25: 402-8.
24. Calvert JW, Gundewar S, Jha S et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008; 57: 696-705.
25. Shibata R, Sato K, Pimentel DR et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK and COX-2-dependent mechanisms. Nat. Med. 2005; 11: 1096-103.
26. Russell RR III, Li J, Coven DL et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest. 2004; 114: 495-503.
27. Shibata R, Ouchi N, Ito M et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 2004; 10: 1384-9.
28. Liao Y, Takashima S, Maeda N et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res. 2005; 67: 705-13.
29. Hardie DG. Minireview. The AMP-activated protein kinase cascade: The key sensor of cellular energy status. Endocrinology 2003; 144: 5179-83.
30. Hardie DG. The AMP-activated protein kinase pathway: New players upstream and downstream. J. Cell Sci. 2004; 117: 5479-87.
31. McCullough LD, Zeng Z, Li H, Landree LE, McFadden J, Ronnett GV. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J. Biol. Chem. 2005; 280: 20493-502.
32. Emerling BM, Viollet B, Tormos KV, Chandel NS. Compound C inhibits hypoxic activation of HIF-1 independent of AMPK. FEBS Lett. 2007; 581: 5727-31.
33. Lefer AM. Attenuation of myocardial ischemia-reperfusion injury with nitric oxide replacement therapy. Ann. Thorac. Surg. 1995; 60: 847-51.
34. Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J. Biol. Chem. 2003; 278: 31629-39.
35. Zhang Y, Lee TS, Kolb EM et al. AMP-activated protein kinase is involved in endothelial NO synthase activation in response to shear stress. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 1281-7.
36. Chen ZP, Mitchelhill KI, Michell BJ et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999; 443: 285-9.
37. Sun W, Lee TS, Zhu M et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006; 114: 2655-62.
38. Szabi BM, van Veldhhuisen DJ, de Graff PA, Lie KI. Alterations in the prognosis of chronic heart failure: An overview of the major mortality trials. Cardiovasc. Drugs Ther. 1997; 11: 427-34.
39. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
40. Paolisso G, Derin S, Marrazzo G et al. Insulin resistance and hyperinsulin emia in patient with chronic congestive heart failure. Metabolism 1991; 40: 972-7.
41. Swan JW, Walton C, Godsland IF et al. Insulin resistance in chronic heart failure relation to severing and etiology of heart failure. J. Am. Coll. Cardiol. 1997; 30: 527-32.
42. Nielson C, Lange T. Blood glucose and heart failure in nondiabetic patients. Diabetes Care 2005; 28: 607-11.
43. Holloszy JO. Exercise-induced increase in muscle insulin sensitivity. J. Appl. Physiol. 2005; 99: 338-43.
44. Gaskin FS, Kamada K, Yusof M, Korthuis RJ. 5'-AMP-activated protein kinase activation prevents postischemic leukocyte-endothelial cell adhesive interactions. Am. J. Physiol. Heart Circ. Physiol. 2007; 292: H326-32.